Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 9, 2025
Best Bodybuilding Supplements: Top Legal Steroids & Supplements For Bodybuilding & Muscle Growth
GlobeNewswire
·
May 9, 2025
Glasgow, May 09, 2025 (GLOBE NEWSWIRE) -- Introduction: Best Bodybuilding Supplements to Accelerate Muscle Growth—Including Legal Steroids In the competitive world of fitness and bodybuilding, every rep, every gram of protein, and every supplement you take …
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
GlobeNewswire
·
May 9, 2025
Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. …
Ocugen Provides Business Update with First Quarter 2025 Financial Results
GlobeNewswire
·
May 9, 2025
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026 Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical …
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
GlobeNewswire
·
May 9, 2025
REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities …
Garuda Therapeutics Announces Name Change to Stratus Therapeutics to Reflect Mission of Pioneering Full Hematopoietic System Renewal
GlobeNewswire
·
May 9, 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Garuda Therapeutics (“Garuda”), a biotechnology company developing off-the-shelf hematopoietic stem cell (HSC) therapies, today announced that it has changed its name to Stratus Therapeutics, Inc. (“ …
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
GlobeNewswire
·
May 9, 2025
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the …
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
May 9, 2025
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Interim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to …
BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President
GlobeNewswire
·
May 9, 2025
SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today …
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
GlobeNewswire
·
May 9, 2025
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy …
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
GlobeNewswire
·
May 9, 2025
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision …
Spectral Medical Announces First Quarter and Provides Corporate Update
GlobeNewswire
·
May 9, 2025
Tigris Trial Enrollment completed Topline results expected to be released in August 2025 Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Spectral Medical …
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
GlobeNewswire
·
May 9, 2025
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May 09, …
Anika Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 9, 2025
First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating …
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
GlobeNewswire
·
May 9, 2025
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in …
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
GlobeNewswire
·
May 9, 2025
ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS …
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
GlobeNewswire
·
May 9, 2025
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master …
Rapid Micro Biosystems Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 9, 2025
Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33 …
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
GlobeNewswire
·
May 9, 2025
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ Chief …
OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
GlobeNewswire
·
May 9, 2025
OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Oxford, UK – 9 May 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 28th Annual …
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
GlobeNewswire
·
May 9, 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the …